The introduction of genes through the skin has been an attractive and dynamic field of research in recent years. It gives the first gleam of hope in therapy for the human genetic diseases that mainly affect this tissue, such as patients that suffer from xeroderma pigmentosum, and who experience increased frequency of skin cancer. The first in vitro experiments were successful in correcting the genetic defects of cells from these patients, the ex vivo reconstruction of corrected cells has been achieved, and the skin of model animals has been treated resulting in cancer prevention. Up to now these efforts have been possible, thanks to the high efficiency of viral vectors that provide gene delivery and expression targeted to many of the different skin cells, including those with proliferative and pluripotent features, such as keratinocytes and epidermal cells of hair follicles. Moreover, progress with several other methodologies qualifies them as alternatives to be explored, in some cases in combination with viral vectors, for skin gene therapy in these patients. Exciting and encouraging new approaches promise benefits to xeroderma pigmentosum patients and their families, and open perspectives of new ways for interfering in gene driven metabolism in the skin.
INTRODUCTION
Easy access combined with its large surface make the human skin an attractive target for gene delivery. One of the advantages of the skin is that gene transfer can be obtained by direct topical or injection applications with minimum invasiveness. Recently many investigators have proposed different strategies to introduce DNA molecules into the organism through the skin, and these efforts will hopefully provide information and improve our understanding of DNA transfer and uptake, as well as achieving efficient gene expression [Hengge and Bardenheuer, 2004] . Potential applications include gene therapy for patients suffering from several human genodermatosis syndromes (such as xeroderma pigmentosum, XP, epidermolysis bullosa and lamellar and Xlinked ichthyosis), DNA vaccination and the local or systemic production of polypeptides of therapeutic interest (such as hormonal, coagulation factor IX, and interleukin). Moreover, one cannot exclude the potential of targeting DNA into the skin for other purposes, such as esthetical assistance and treatments for skin cancer and aging.
Several non-viral methods have been proposed and tested for gene delivery in and through the skin, which include DNA molecules chemically wrapped with substances that facilitate cell uptake, with liposomes as the most popular formulations, besides physical devices that take DNA direct to the viable cells of the skin, such as gene gun, microneedles and electroporation. These methods result in gene delivery to several of the skin cells, although, until now with *Address correspondence to this author at the Depto. de Microbiologia, ICB, USP, Av. Prof. Lineu Prestes, 1374, Ed. Biomédicas 2, São Paulo, 05508-900, SP, Brazil; limited efficiency, and are detailed in excellent recent reviews [Hengge and Bardenheur, 2004; Birchall, 2006; Hoffman, 2006; Foldvari et al., 2006] . Viral vectors, even though more expensive and complex to generate, appear as effective alternatives that provide gene uptake and expression in many of the skin cells. Human viruses have systems for genome delivery into the cells that have evolved for billions of years, so, working with viral vectors, we merely try to take advantages of these highly specialized tools for transducing genetic material accurately into the nuclei of human cells. In this review, we will focus on the potential of skin gene therapy for patients with the human syndrome XP, who suffer from deficiencies in the metabolism of damaged DNA, badly affecting skin sensitivity to sunlight. The main viral strategies to correct the genetic defect of cells from these patients will be described, together with an overview of other important techniques that enlarge the possibilities and create alternatives to achieve efficient gene delivery in the skin of these patients.
Barriers and Targets for Gene Therapy: The Skin Structure Itself
Although gene delivery into the skin has many appealing potentials, it should be kept in mind that this tissue has major functions to provide physical and immunological barriers to protect the organism against environmental hazards and pathogen aggression. These features constitute clear obstructions to delivery protocols and should be well understood in order to search for procedures that can help to circumvent them. Different types of cells are found in the skin, grouped into two main structures: the most external layers known as the epidermis, derived from the embryonic ectoderm, and the internal layers referred to as dermis of mesenchymal origin (Fig. 1) [Hopewell, 1990] . The outermost layer is the stratum corneum, composed of flattened dead keratinized cells, which are periodically replaced by cells from the deeper layer, the stratum granulosum. The stratum corneum has protective functions and it is the main obstacle for transdermal delivery. Below, the stratum spinosum is composed of viable cells, but it is in the basal layer or stratum basal of the epidermis where keratinocytes with proliferative potential are found. These cells are important targets for gene therapy as they may produce many of the upper layers of the skin. Other different types of cells are also found in the stratum spinosum, with many different functions, such as Langerhans and Merkel cells, and melanocytes. When considering preclinical experiments with animal models, one very important point is that the human epidermis is rather thick, with many cell layers, being comparable to other species, such as the pig, but very different from the very thin epidermis of common laboratory rodents (only two to five cell layers). The deeper layer of the skin is the dermis, very rich in collagen fibers, with a cell population mainly composed of fibroblasts. Skin vascularization is provided by the blood vessels present in the dermis, where the nerve fibers are also found. In addition, the dermis contains skin appendages, such as sweat and sebaceous glands, and hair follicles. The hair follicles, where expression of transduced genes has been already achieved, are of particular interest for gene therapy, as it has been discovered that they contain highly pluripotent stem cells [Hoffman, 2006] .
Taking Care with Sunlight
As the skin is the external part of our body, it is obviously subject to environmental aggression. Sunlight is one of the most important examples of damaging agents, known to be a direct cause of skin degeneration processes, such as cancer and aging. Although the ozone layer in the stratosphere constitutes an efficient shield of protection, part of the highly energetic ultraviolet (UV) components of the sunlight still reaches the Earth's surface and can damage living organisms. UV is basically divided according to its energy and wavelength: UVC (200 to 280 nm, highest energy), UVB (280 to 320 nm) and UVA (320 to 400 nm, lowest energy). The highly harmful effects of UVC light are completely blocked by the ozone layer, however, part of the UVB and most of the UVA still reach the Earth's surface, and both can damage the genetic material of skin cells. UVA light can penetrate deeper into the skin, and causes DNA damage mostly by indirect effects, generating oxygen radical species that react with nitrogen bases, resulting in base alterations and breaks in the DNA molecule. On the other hand, UVB can be directly absorbed by DNA bases, producing two main types of damage, the cyclobutane pyrimidine dimers (CPDs) and pyrimidine-pyrimidone 6-4 photoproducts (6-4PPs). These lesions cause distortions in the DNA molecule, and are important blocks to replication and transcription machineries. For our protection, the cells have evolved several DNA repair systems that either remove these lesions, or help to tolerate them. However, when the dose of irradiation is too high, the induction of these DNA damages in the skin promotes cell killing by apoptosis (one of the effects observed in sunburn) and, at long term, tumor formation and aging.
Xeroderma Pigmentosum Disease: The "Children of the Moon"
The most dramatic examples of such harmful effects of sunlight are observed in patients that suffer from XP. This is a hereditary syndrome, transmitted by an autosomal and recessive trait, with an estimated frequency of approximately one per 500,000 newborns. XP patients present high photosensitivity in the regions of the skin that are normally exposed to the sun. Severe skin sunburns normally appear as the first symptoms of XP patients, still in their early childhood, evolving to strong pigmentation, actinic keratoses, and then to skin cancer. The neoplasms normally occur very early in their lives (under 10 years old), with a frequency of 2,000-fold higher, when compared to the population as a whole. Most of the tumors in these patients are basal and squamous cell carcinomas (originated from keratinocytes), but XPs are also predisposed to malignant melanoma. Although the skin photosensitivity of these patients is certainly the most impressive feature, XP may also develop internal tumors with a higher frequency than the population in general, eventually presenting neurological problems [Kraemer et al., 1987; Lehmann, 2003; Cleaver, 2005] . Up to now, possible treatments available for XP patients are extremely limited, the best way to avoid premature skin cancer being to strictly avoid sunlight since very early infancy. For this reason, these kids have been sometimes designated as "children of the moon". Therefore, their families need frequent and proper medical advice from dermatologists, besides which, surgical tumor resection has to be carried out as soon as they are detected. At least in developed countries, strict solar protection from an early age, which includes UV-resistant clothing and face visors, reduces the skin related problems for these patients. In fact, for some families the neurological problems have become the main concern. Unfortunately, in developing countries, where medical care is deficient, the lack of information and diagnosis often leads to dramatic consequences.
The Molecular Defect on DNA Repair
The molecular nature of the genetic defect of XP patients was first established when cells from these patients were shown to be deficient in their ability to perform DNA repair, implying that sunlight-induced lesions were not removed from the genetic material of these patients, exacerbating their harmful effects [Cleaver, 1968] . This discovery was the starting point for understanding the molecular defects of XP cells, and of how human cells handle lesions in their genome. It turned out that most of the XP patients are deficient in Nucleotide Excision Repair (NER), a highly conserved and versatile mechanism that removes different types of DNA damage that cause double helix distortions, such as UV-induced lesions, CPDs and 6-4PPs. More than 30 proteins act during the processing of DNA lesions by NER, including seven that are functionally impaired in XP patients (known as XPA to XPG proteins). Basically, the NER pathway involves the following steps: recognition of the DNA lesion, opening of the DNA helix by the concerted action of helicases, dual incision of the damaged strand at both sides of the lesion by endonucleases, removal of the damaged oligonucleotide (24-32mer), DNA synthesis by DNA polymerase and ligation by DNA ligase (Fig. 2) [Costa et al., 2003] . Curiously, some XP patients have normal NER ability, but lack the functional translesion synthesis by DNA polymerase eta, a damage-tolerance mechanism that supports the direct bypass of DNA lesions, which cannot be accomplished by the replicative DNA polymerases [Friedberg et al., 2005] . The absence of the DNA polymerase eta activity makes them clinically similar to the classical XP patients and they are referred to as XP variants.
It has been demonstrated that the unrepaired DNA lesions in XP cells promotes mutagenesis, which is the main reasonable explanation for increased tumor frequency observed in XP patients. In fact, research in XP cells has provided an enormous amount of information on the mechanisms of carcinogenesis, but little can still be done to relieve the difficult life of these patients and their families. For the moment, identification of the gene that is deficient in a XP individual may help to confirm diagnosis, and to predict clinical prognostic, guiding appropriate genetic counseling for the patient's parents.
Targeting Skin Cells by Protein Delivery
One of the recent proposals for XP treatment is based on a biotechnological approach for restoring dysfunctional or accelerating DNA repair processes through the topical application of DNA repair enzymes via liposomes [Yarosh, 2004] . Two bacterial DNA repair enzymes, CPD-photolyase and T4-endonuclease V (T4-endoV), were encapsulated in liposomes to target skin cells. The CPD-photolyase, when illuminated by visible light, directly and specifically reverts CPDs to the original monomers. The T4-endoV is originally from the bacteriophage T4, and cuts the DNA backbone at the site of CPDs. The resulting product, a single strand break, can be processed by another DNA repair system to remove the lesion and restore the original DNA sequence, even in XP cells [Kraemer and DiGiovanna, 2002] .
Clinical testing shows that liposome-encapsulated T4-endoV (T4N5) or CPD-photolyase repairs CPDs in the skin of human subjects, and prevents UVB-induced immunosuppression. Both effects have been linked to the partial prevention of skin cancer by T4N5 application in DNA repairdeficient XP patients [Yarosh et al., 2001] . In that study, the T4N5 liposome lotion was applied daily to the skin of twenty XP patients for one year, while another eight patients received placebo liposome lotions. The data clearly indicated that this treatment significantly reduced the rate of new actinic keratoses and new basal-cell carcinomas (68% and 30%, respectively) in these patients. Moreover, neither signs of immune responses against the bacterial enzyme nor adverse effects were observed. The success in this treatment is very exciting and optimistic for XP skin therapy, although the continuing and careful use of T4N5 liposome lotion may be necessary throughout life in order to avoid further DNA damage. It should be pointed out, however, that CPDs are not the only type of lesions generated by sunlight, as the 6-4PPs may also play an important role in carcinogenesis, especially in XP patients . T4-endoV and CPD-photolyase do not actually restore the NER pathway, only acting on CPDs. An alternative to repair both types of photolesions could be the delivery of 6-4PP-photolyase, together with CPD-photolyase, employing a similar liposome encapsulation. In fact, the use of such an enzyme may improve skin protein therapy for XP patients.
APPROACHES FOR XP GENE THERAPY
The genes responsible for this syndrome have all been duly identified, and are named as XPA through XPG, and POLH for the XP variant (their genome location and the known functions of their respective protein products are listed in Table 1 ). Therefore, XP patients are appropriate candidates for cutaneous gene therapy, which appears as an exciting and simple approach. The idea is to provide the missing gene to the skin cells of these patients, correcting their ability to perform efficient DNA repair or DNA translesion synthesis, and reducing the risks of developing skin tumors. It should be noted, however, that for skin therapy there is a need for efficient gene correction in most (if not all) skin cells, as the cells that remain DNA repair deficient would still have high risk to develop cancer. Furthermore, the skin is just part of the problem for many of the XP patients, as neurological abnormalities and internal tumors will probably need a combination of skin therapy together with other therapeutic protocols.
Efforts have recently been made in the search for efficient approaches aiming gene correction of skin cells in preclinical experiments, with results that are starting to provide some hope, but certainly much has still to be done. At present, only viral vectors have been successful in correcting XP phenotype in vitro, with different strategies for reaching skin cells. In fact, these viral vectors constitute the most efficient tool for competent gene transfer into cells, and several alternative strategies seek to improve efficacy, specific cell targeting and safety [Thomas et al., 2003] . Various viral systems have been adapted to achieve a high efficiency of gene transfer, and the best known are retroviruses (including lentivirus), adenoviruses, and adeno-associated viruses. They all present advantages and disadvantages that should be taken into account before being chosen for specific purposes. The progress made with these vectors for XP gene therapy will be described below.
Recombinant Retroviral Vectors and Skin Reconstruction
Retroviruses contain a single-stranded RNA molecule as genome, and replicate by reverse transcription to a linear double-stranded DNA (dsDNA), which is integrated into the host cell genome. Thus, vectors that keep these features allow for stable gene transmission through cell generations and, as a consequence, they have the potential of permanent expression of the delivered transgene [Baum et al., 2006; Zhang and Godbey, 2006] . This property offers a potential for the long-term cure of inherited monogenic diseases, such as XP.
The ability of retroviral vectors to correct XP genetic defects was demonstrated in XPA -/-, XPC -/-and XPD -/-fibroblasts. The DNA repair and UV-survival of the transduced fibroblasts were completely reversed to levels of wild type cells, providing the basis for further experiments directly in skin cells, such as the keratinocytes [Quilliet et al., 1996; Dumaz et al., 1998 ]. Several strains of primary XP keratinocytes and XP fibroblasts from skin biopsies of XPC -/-patients were cultivated and succeed to reconstruct XP skin in vitro, with an epidermis and a dermal equivalent. The DNA repair deficiency of the reconstructed XP skin was confirmed by the persistence of UVB-induced DNA damage in all epidermal layers [Bernerd et al., 2001 ]. These results gave rise to an opportunity for ex vivo gene correction. A recombinant retroviral vector based on Moloney murine leukemia virus (MoMLV), and bearing the XPC cDNA under the transcriptional control of 5' viral long terminal repeat (LTR), has been successfully used to infect and complement the absent function in primary keratinocytes derived from two different XPC -/-patients [Arnaudeau-Bégard et al., 2003] . In these cells, the level of the exogenous XPC protein was in the range of the endogenous protein in wild type keratinocytes. In addition, transgene expression could be followed up to 6-7 weeks after antibiotic selection, this suggesting the stability of this protein. More important, the reintroduction of the wild type XPC allele in XPC -/-keratinocytes was accompanied by increased resistance to UVB irradiation, as could be clearly observed by cell survival and DNA repair assays. At the biochemical level, it could also be seen that the exogenous XPC protein reduced the expression of 1-integrin in these keratinocytes, a protein that is normally increased in the skin of XPC -/-patients. The corrected keratinocytes were able to reconstruct skin in vitro, and histological staining indicated an excellent capacity of the infected keratinocytes to complete full-thickness epidermal morphogenesis with satisfactory features of stratification, indicating that transduction as well as selection steps did not alter keratinocyte physiology. Taken all together, these findings open really exciting possibilities in the treatment of XP patients, granting definitive correction of their keratinocytes, and avoiding undesirable immune responses by correcting and reintroducing their own cells. The general rationale for the full proposed ex vivo protocol using these retroviral vectors has been previously reviewed (Fig. 3) [Magnaldo and Sarasin, 2004; Magnaldo, 2004] . Basically, primary epidermal keratinocytes can be obtained from a biopsy of the patient, and cultivated. These cells can be modified ex vivo using the retroviral vector carrying the XP gene, and by using appropriated cell culture conditions the skin is reconstructed and amplified in vitro. Preclinical experiments have demonstrated the success of this strategy, with full correction of XPC -/-keratinocytes, up to this step. The epithelial sheets from corrected cells can then be engrafted back to the patient, providing a skin that would be DNA repair protected from sunlight incidence. The long-term expression of XPC protein in vivo will soon be tested by grafting genetically corrected human skin onto immunodeficient laboratory animals [Frechet et al., 2006] . Fig. (3) . Representation of ex vivo correction of human XPC -/-keratinocytes through retroviral vector. Keratinocytes from two XPC -/-patients were collected (1), cultivated in vitro (2), and then transduced with MoMLV-XPC (3), a recombinant retroviral vector carrying the human XPC cDNA. The XPC-transduced keratinocytes (4) were successfully used to reconstruct human skin in vitro (5), which is basically corrected for the XP phenotype. Dashed line raises the possibility of engraftment of the reconstructed skin directly on XP patients. Similar approaches have also been developed for ex vivo skin gene therapy of the inherited disease junctional epidermolysis bullosa (JEB), characterized by loss of cohesion between the epidermis and the dermis. This disease is caused by mutations in genes encoding laminin 5 or other components of the hemidesmosome. Full phenotypic correction of the adhesion properties of JEB keratinocytes was observed in the reconstructed skin from cells infected with retroviral vectors expressing laminin 5. Genetically modified epidermal sheets maintain long-term expression of the transgene after transplantation on immunodeficient animals [Dellambra et al., 2000] . The ex vivo approach for JEB gene therapy was recently validated in an animal model (dog), before undertaking human clinical trials [Spirito et al., 2006] .
On the other hand, caution should be taken when considering the use of retroviral vectors for gene delivery purposes. The main potential risk in these tools is insertional mutagenesis resulting from random retroviral integration, which could either activate proto-oncogenes over long distances or inactivate tumor-suppressor or essential housekeeping genes, ultimately leading to malignancies [Young et al., 2006] . In fact, clinical gene therapy results strongly implicated retrovirus integration into host cell genome in tumorigenesis mechanisms, causing concern as to biosafety in gene therapy protocols involving retroviral vectors. Therefore, the application of retroviruses ex vivo for skin XP gene therapy will probably have to devise means to check for integration sites before engraftment.
Lentiviral Vectors for Ex Vivo and In Vivo Gene Transfer
Lentivirus is a subclass of retroviruses that is able to infect both proliferating and non-proliferating cells, since the viral integration complex can be transported through an intact nuclear membrane via the nucleopore. Thus, lentiviral vectors provide possibilities for transducing cells that are in a non-dividing state, such as quiescent cells. As a consequence, they can be used for ex vivo transfer, or eventually for direct in vivo applications. In addition, these vectors yield high transduction efficiency and sustained gene expression in vivo, and do not appear to induce a significant host immune response [Amado and Chen, 1999; Lotti and Mavilio, 2003] . Nowadays, most of the lentiviral vectors used for gene transfer are derived from the human immunodeficiency virus (HIV), though vectors based on equine infectious anaemia virus have also been developed [Young et al., 2006] .
Early results using lentiviral vectors carrying reporter genes display efficient, stable and prolonged expression of the transgene both in vitro and in vivo in muscle, liver and neuronal tissues [Naldini et al., 1996; Kafri et al., 1997; Blomer et al., 1997] . In the skin diseases field, the results are also really exciting. Lentiviral vectors have been recently employed in studies involving recessive dystrophic epidermolysis bullosa (RDEB). Similar to JEB, this is an inherited mechanobullous skin disorder, in this case caused by mutations in the gene COL7A1, which encodes type VII collagen, a major component of anchoring fibrils that adheres the epidermal layer of skin onto the dermis [Uitto and Christiano, 1994] . In an effort to achieve efficient, sustained and corrective expression of COL7A1, a recombinant lentiviral vector was directly injected into the skin of RDEB model mice. After intradermal injection, type VII collagen was found in the skin, in both fibroblasts and endothelial cells. Moreover, this protein could be transported to, and incorporated into, the basement membrane zone, thus correcting the RDEB disease features [Woodley et al., 2004] .
Although lentivirus based-therapy has not been used so far for in vivo protocols in the XP field, HIV based-lentiviral vectors carrying XPA, XPC and XPD cDNAs have been recently constructed and employed in cell culture assays. The DNA repair-defective phenotype of SV40-transformed and primary fibroblasts from XPA -/-, XPC -/-and XPD -/-patients has been rescued after infection with the respective recombinant lentivirus, as seen through cell survival and DNA repair assays employing UV irradiation. In addition, the UVresistance recovery in these cells was even observed 3 months after transduction, without loss of transgene expression, providing proof of principle that this strategy may be worthwhile pursuing [Marchetto et al., 2006] . The authors also propose that the highly efficient capacity of lentiviruses to infect post-mitotically neurons ] make these vectors an attractive alternative to understanding the neurodegenerative disorders observed in 15 to 40% of XP patients.
Skin Gene Delivery by Recombinant Adenovirus
Adenoviruses are non-enveloped, icosahedral particles 70-90 nm in size, with a 36 kbp-long linear double stranded DNA genome, with inverted terminal repeats (ITRs) of 100-140 bp in length at both ends acting as cis elements during viral replication [Rux and Burnett, 2004; Gonçalves and deVries, 2006] . Over the last decades, recombinant adenoviruses have been used as vehicles of gene transfer with high success. Some of the important reasons for the choice of adenoviral vectors for gene therapy are: i) many human and animal adenoviruses are non-pathogenic for their natural hosts, (ii) a variety of both proliferating and quiescent cell types, such as epithelial cells, fibroblasts, hepatocytes, endothelial cells and stromal cells, can be infected by these viruses, and, (iii) adenoviral vectors can be easily grown to very high titers, offering a means of infecting a large number of target cells [Bangari and Mittal, 2006] .
In first generation adenoviral vectors, the E1 (E1A and E1B) gene is deleted and the virus is propagated in particular cell lines, such as HEK 293, that provide E1 proteins in trans. The non-essential E3 gene is often deleted to enlarge the packagable size limit for foreign genes [Bett et al., 1994] . Experiments employing first generation adenoviral vectors targeting XP disease have recently been developed [Armelini et al., 2007] . Human-derived XP fibroblasts, from XPA, XPC, XPD and XPV complementation groups, were successfully transduced by recombinant adenoviruses. XP cell populations infected with the respective virus were demonstrated to express high levels of the transduced gene product. DNA repair levels were recovered, and resistance to UVirradiation of transduced-XP cells was reverted to levels comparable to wild type cells, thus demonstrating functional correction of the XP phenotype [Muotri et al., 2002; Armelini et al., 2005; Lima-Bessa et al., 2006] . Moreover, although adenoviral transduction is usually just transient, sustainable XPA protein expression and parallel increased UVirradiation resistance were obtained even two months after cells had been infected with AdyXPA, the adenoviral vector carrying the human XPA cDNA [Muotri et al., 2002 ].
AdyXPA was also tested in vivo in XPA -/-knockout mice (Fig. 4) [Marchetto et al., 2004] . These knockout mice are interesting models for investigating human XP disorder as they present phenotypes that are quite similar to XP patients. Thus, they develop UV radiation-induced skin tumors at high rates and also internal tumors by the administration of drugs [Tanaka et al., 2001; Meira et al., 2001] . The adenovirus preparation was injected subcutaneously at the depilated dorsal region of the XPA -/-mice. Efficient expression of the human XPA protein, detected by immunohistochemistry, was observed in several skin layers, including potentially replicating keratinocytes in the epidermis, dermal fibroblasts and also in cells of skin appendages. The mice were UVBirradiated, and the effects on their skin were analyzed by direct observation and histology. Two months after irradiation, all mock-infected XPA -/-mice presented persistent scars and skin hyperkeratosis, which five to six months later evolved to skin tumors (squamous cell carcinomas). On the other hand, both wild type and AdyXPA-infected knockout mice presented only a mild epidermal hyperplasia in the first weeks after UVB irradiation, restoring normal epidermal status later on. None of twenty AdyXPA-infected knockout mice developed tumors. Therefore, these experiments demonstrated the potential use of adenoviral vectors to efficiently transduce functional genes to skin cells, since this approach prevented UVB-induced skin carcinogenesis in knockout mice.
The results described above are very exciting as a basis for skin gene therapy in XP patients. Nevertheless, adenoviral vectors present certain particular issues that should be addressed before moving forward to clinical trials. These vectors normally trigger strong immune responses in the host, leading to transgene expression reduction, even very shortly after in vivo infection. Although these effects still need to be investigated for skin infection, immune responses may also restrict the efficiency of repeated in vivo adenovirus administration [Gonçalves and deVries, 2006] . Thus, several strategies are being proposed in order to circumvent adenovirus mediated immune responses. One approach is to shield the adenoviral coat proteins from recognition by the host immunological system, using different chemical formulations. This has been achieved by chemical modification of coat proteins with polyethylene glycol, an immunologically inert polymer [Croyle et al., 2001] , or through encapsulation of the adenoviral vector by microspheres composed of sodium alginate or poly(lactic-glycolic) acid [Beer et al., 1998; Sailaja et al., 2002] . More recently, several groups have shown that liposome-complexed adenovirus may also improve the ability of gene transfer to cells, reducing immunologic mediated neutralization, as will be discussed below. Another approach is to modulate host immune responses by the use of immunosuppressive drugs, immediately before in vivo adenovirus application [Ritter et al., 2002] . These strategies have been shown to improve the time of gene expression in vivo, without substantially reducing the efficiency of infection, and should be tested in order to improve the efficiency of XP recombinant adenovirus administration directly into the skin.
Efforts have also been dedicated to the development of new recombinant adenovirus aiming at reducing the immune responses from the host. In these vectors, most of the adenoviral genome was removed from the vector sequence, which were then named "all deleted", "gutless", "high capacity" or "helper-dependent" adenoviruses. Virus production requires cell co-transfection with two complementary plasmids, one that contains all the viral genes required for replication, but carrying a conditional defect in the packaging domain, while the other, which is the vector itself, contains only the viral ITRs, the normal packaging recognition signal, and the therapeutic gene sequence. These vectors were shown to generate high virus titer, and, more important, to mediate long-term transgene expression, with low toxicity and immunogenicity. Unfortunately, gutless virus preparations still carry high levels of replication competent virus, thus restraining their use in human clinical trials [Volpers and Kochanek, 2004; Alba et al., 2005] . Fig. (4) . Representation of in vivo assays employing adenoviral vector carrying the human XPA cDNA (AdyXPA). The plasmid for the vector was transfected into HEK 293 cells (1) in order to produce infectious recombinant adenoviral particles, which could be followed by GFP visualization at fluorescence microscopy (2). After 2 rounds of amplification in this particular cell line, AdyXPA was purified (3), and then subcutaneously injected into dorsal region of XPA -/-knockout mice (4). The expression of GFP and XPA proteins in the skin of transducedknockout mice was confirmed (5). These mice were then challenged with UVB irradiation (6), and the virus was shown to protect the skin from damage and prevent the formation of skin tumors (7).
Recombinant Adeno-Associated Vectors (rAVV): An Alternative for Long Term Gene Expression
Human adeno-associated viruses (AAV) were first isolated as contaminants of adenoviral preparations, and have never been linked to any human disease. These viruses are non-pathogenic, and normally depend on helper viruses, either adenovirus or herpes simplex virus, for productive infection and replication, but in the absence of these, AAV may establish a persistent infection, either by site-specific integration in the host genome or as an episomal genome.
AAV is a parvovirus that packages as a single-stranded DNA genome of approximately 4,700 nucleotides, with palindromic regions at either end, also named ITRs. The ITRs are arranged so that each terminus can fold into a T-shaped DNA secondary structure through base-pairing between palindromic subregions, which are essential for conversion of the single-stranded virion DNA to dsDNA template for transcription and replication. AAV-derived vectors package and deliver an inactive ssDNA genome that is converted into an active dsDNA in the nucleus. Except for first generation vectors, most rAAVs are devoid of all viral genes, namely the rep and the cap genes that encode, respectively, nonstructural Rep proteins involved in the replication of the viral genome, and the viral structural proteins, which constitute the viral capsid [Wu et al., 2006] .
Eleven strains (serotypes) of AAV have been identified so far, in addition to more than a hundred sequences corresponding to novel clades of AAV [Gao et al., 2004; Gao et al., 2005] . Gene transfer vectors have been derived from AAV1 to 9, using pseudotyping strategy, which consists of a recombinant genome framed by the ITR of AAV serotype 2 and a capsid of a different serotype [Le Bec and Douar, 2006] . Each pseudoserotype has a different cell tropism implicated in the proteins that constitute the capsid of the rAAV that binds to a receptor in the cell surface. For example, AAV2 interaction with heparan sulfate proteoglycans is important for cell binding and transduction [Kashiwakura et al., 2005] . Subsequent interactions with the human fibroblast growth factor receptor 1 (FGFR1) [Qing et al., 1999] and integrins v 5 / v 1 [Summerford et al., 1999] have also been reported. Interesting for skin gene therapy approaches, the heparan sulfate proteoglycans are highly expressed in keratinocytes [Jalkanen et al., 1988] .
The ability of rAAV to efficiently infect skin tissue has been recently validated. Curiously, previous work has demonstrated that AAV2 viruses may replicate, devoid of any helper virus, in a model culture of primary raft skin tissue derived from human keratinocytes [Meyers et al., 2000] . Consistent with this observation, rAAV2 vectors carrying the reporter genes LacZ ( -galactosidase) or GFP (green fluorescent protein) were observed to efficiently transduce human keratinocytes [Braun-Falco et al., 1999] , with transgene expression lasting for up to 50 days. More recently, a similar work confirmed gene transfer into keratinocytes ex vivo, which were then differentiated to reconstruct transgenepositive recombinant skin, using the organotypic epithelial culture system [Agrawal et al., 2004] . The transduction of the reporter gene GFP has been confirmed in human keratinocytes, using a new generation of rAAV2 vectors in an adenovirus-free preparation, and the gene transfer to these cells was enhanced by the use of proteosome inhibitors [Braun-Falco et al., 2005] .
In animal models, rAAV was also shown to be capable of gene transfer directly to the skin in vivo. Subcutaneous injection of rAAV in mice resulted in high and long-term (up to nine months) expression of secreted proteins, such as murine erythropoietin, and LacZ [Donahue et al., 1999] . In a key work concerning skin gene therapy by these vectors, efficient skin gene transduction was also shown in experiments in vivo, employing miniature pigs as a model similar to human skin [Hengge and Mirmohammadsadegh, 2000] . This work demonstrated that dermal injection of rAAV2 vectors carrying the reporter gene LacZ resulted in transgene expression in porcine skin. Moreover, although the target area was still small, expression of -galactosidase was observed not only in dividing and post-mitotic keratinocytes, but also in skin appendages, such as the epithelial cells of hair follicles and sweat glands. Long-term expression was successfully achieved, as -galactosidase activity was detected in the skin for over 40 days, beyond the regular three weeks for epidermal cell turnover. However, this work also revealed that repetitive vector administration was accompanied by a reduction in transgene expression, a limitation that probably occurred due to immunological neutralization of the injected viruses, as it had previously been observed for early rAAV vectors [Halbert et al., 1997] . More recently, although not targeted to the skin, an encouraging work confirmed the ability of long-term AAV mediated gene transfer. In phase I clinical trials, administration of an rAAV vector carrying the gene responsible for the coagulation factor IX in the skeletal muscle of eight hemophilic patients proved to be safe, and the transgene was shown to be expressed in therapeutical levels for at least 10 months [Jiang et al., 2006] . The same work reports similar experiments in hemophilic dogs, where factor IX was detected in muscle biopsies and circulation for over four years.
So far, these vectors have not been employed in experiments targeting genodermatosis, such as XP disease. Moreover, rAAV transduction in the skin does not seem to be as efficient as transduction mediated by adenoviral vectors. However, some features of rAAV vectors make them an attractive candidate for XP skin gene therapy assays. These features include the repeated reports of long-term transgene expression mediated by rAAV, very low risk, if any, of pathogenicity in humans, and the availability of new generation rAAV vectors (adenovirus-free), which are potentially less immunogenic, and thus probably more convenient for readministration into the skin. Hence, in vivo experiments have already been designed to test these vectors as a vehicle for XP gene transfer directly into the skin.
Skin Gene Therapy by Non-Viral Methods
The concern for safety, as regards viral vectors, makes the use of non-viral methods an attractive approach for gene therapy. Moreover, these methods are less expensive, easily manufactured and suitable for plasmids of various sizes, having been extensively employed for skin gene delivery. Nonetheless, compared to viral vectors, non-viral techniques have always failed to provide efficiency for gene transfer that would be satisfactory for genodermatosis diseases, such as XP. Up to now, they are attractive alternatives for the expression of protein to the antigen presenting cells existing in skin epidermis and dermis, for DNA vaccine purposes. Many recent reviews provide more complete details of non-viral strategies to deliver genes into skin tissues [Hengge and Bardenheur, 2004; Birchall, 2006; Hoffman, 2006; Foldvari et al., 2006] , but we will give a brief description of the different approaches, mainly with the specific aim of calling attention to the possibilities of using combined formulations, and eventually improve gene delivery through viral vectors.
As stated before, the skin is itself a strong barrier for gene transfer into epidermal or dermal cells. Unfortunately, simple application of a DNA solution into the skin does not result in cutaneous gene transfer. DNA molecules have to cross the external non viable skin layer, the stratum corneum, and transverse cell membranes to reach the nuclei, where they can finally be expressed. Several physical devices and chemical delivery strategies have been designed to achieve this goal, with limited success in terms of gene expression.
Many of the methods for gene delivery employ physical force in order to introduce DNA into the cells. For example, electroporation involves the application of short and controlled electrical pulses to target tissue, transiently permeabilizing cell membranes by forming brief aqueous pathways across them, thus allowing DNA molecules to enter the cells [Weaver, 1993] . Applications directly onto the skin can cause burning of the superficial stratum corneum that heals in a few days, normally with no scarring [Foldvari et al., 2006] . In fact, intradermal injection of DNA followed by noninvasive in vivo electroporation results in a several-fold increase in skin gene expression, when compared to naked DNA [Glasspool-Malone et al., 2000; Drabick et al., 2001; Zhang et al., 2002] . The application of this technique for gene delivery is of substantial interest for DNA-induced cutaneous vaccination [Zhang et al., 2004] .
The ability to generate micropores in the skin, to allow access to the viable epidermis, is normally called microporation. For example, a vaporization process promotes the removal of tiny areas of the stratum corneum, generating the micropores. This methodology has been used with success in combination with adenoviral vectors, improving gene expression 100-fold. This has initially been used as a skin directed vaccination protocol [Bramson et al., 2003 ], but it may also be useful in gene correction therapy. Another approach for transdermal gene delivery, which significantly improves the transport of molecules across the skin, utilizes micrometer-sized silicon needles, thereby enabling diffusion of the molecules from the stratum corneum to the underlying viable epidermis and dermis. The length of the microneedle is controlled to ensure that the depth of penetration does not reach the nerve fibers and blood vessels that primarily reside in the dermal layer. Therefore, the delivery of DNA molecules, and gene expression into the skin can be achieved without causing pain or bleeding at the site of application [Coulman et al., 2006; Birchall, 2006] . Data are encouraging, although expression is normally limited to the cells that are close to the micropores. Since the size of such microneedles is much larger (80 μm in diameter) than viral vector particles (close to 100 nm), this device may help cutaneous delivery, improving their ability to be propagated in deeper skin layers, such as the epidermis basal layer or even dermal cells.
The particle bombardment method provides an alternative approach for gene transfer. Transient expression of the luciferase gene from different promoters could be assessed in 5 different rat tissues, including the epidermis and dermis, after bombardment gene transfer [Cheng et al., 1993] . By the end of the 1990s, a study comparing different non-viral methods of gene delivery showed that the gene LacZ could be detected up to 4 weeks after skin bombardment, whereas DNA intracutaneously or epicutaneously delivered was followed up to 1 week only [Udvardi et al., 1999] . In more recent experiments, rat skin bombardments with a plasmid containing the human agouti signaling protein cDNA resulted in transient changing of skin colour, which was more pronounced 14 days after bombardment [Yang et al., 2004] .
Coating DNA molecules, with lipids emulsions (=lipo-plex) and several cationic polymers (such as polylysine, polyhistidine, polyethyleimine; =polyplex), is becoming increasingly popular for gene delivery into cells in vitro and in vivo. Although the exact physical properties of DNA interaction with these molecules are not characterized, cationic liposomes and polymers can interact with negatively charged DNA molecules, and the resulting positively charged complexes do not offer electrostatic barriers with the negatively charged cell membrane. These DNA complexes are taken by the cells through endocytosis, some of the DNA molecules then scape from the lysosomes into the cytoplasms and have to be transported to the nuclei [Karmali and Chaudhuri, 2006] . By aiming gene delivery into the skin, lipid-DNA complex lotions are especially attractive in topical applications for treating large surface areas. With this technique, gene expression has been successfully achieved, although efficiency is low and transient [Hengge, 2005] . Interestingly, liposomes applied onto the skin specifically target hairfollicle cells [Li and Hoffman, 1995; Domashenko et al., 2000] . These cells have been discovered to preserve stem cell properties, being highly pluripotent. In fact, GFPtransduced hair follicle cells were shown to differentiate into neurons after transplantation to the subcutis of nude mice [Amoh et al., 2005a] , and support healing of damaged peripheral nerves [Amoh et al., 2005b] . These results suggest that hair follicle stem cells may provide an important accessible and autologous source of adult stem cells for regenerative medicine, and a highly relevant target for gene therapy [Hoffman, 2006] .
On one side, the low immunogenicity of liposomes, and on the other the high efficiency of adenoviral vectors may be used in combination in order to improve gene transfer methods into human cells. In fact, cationic molecules and liposomes encapsulate the negatively charged adenoviral particles, facilitating their uptake and increasing gene expression in some cell lines in vitro and in the nasal epithelium of cystic fibrosis mice in vivo [Fasbender et al., 1997] . Coating the adenoviruses with polycations, such as poly-Llysine, was also shown to require reduced doses of vector, decreasing immune responses to adenoviruses, and improving the efficacy of readministration protocols [Kaplan et al., 1998 ]. Adenoviral vectors are also limited by the requirements of their specific cell receptor (CAR, Coxsackie adeno-virus receptor). Cholesterol modified liposomes were shown to allow adenovirus vectors to target cells lacking CAR, also providing resistance (in vitro and in vivo) to human antiadenoviral antibodies [Yotnda et al., 2002] . More recently, different formulations of adenoviral-liposome complexes have both confirmed and optimized the features conferred to the vectors, such as increasing gene expression in different tissues, shielding to the immunological system and reducing toxicity [Price et al., 2005; Steel et al., 2005; Snoeys et al., 2006] . The positive data should encourage future efforts to test the effects of coating adenoviral vectors with cationic lipids or polymers in transdermal gene delivery.
Finally, recent progress has been made towards the use of non-viral gene delivery for sustainable gene expression, through site-specific integration into a safe region of the host genome [Ginsburg and Calos, 2005] . The idea is to use bacteriophage genes that promote site-specific recombination (such as the integrase from Streptomyces phage phiC31), to insert transgenes in the genome of mammalian cells that are not associated with essential functions or with tumor progression. This elegant strategy has been successfully applied in human keratinocytes from patients with the skin disorder RDEB, caused by mutations in the COL7A1 gene. Skin reconstructed from the transformed cells displayed functional type VII collagen protein expression, anchoring fibril formation and dermal-epidermial cohesion, that is fully correcting the skin-genetic defect [Ortiz-Urda et al., 2002] . These data provide hope for the use of this non-viral genetic correction in ex vivo protocols for human skin-genetic disorders.
CONCLUSIONS AND PERSPECTIVES
Over the last five years, exciting progress has been achieved in investigations of skin-mediated gene transfer. Studies are still based on preclinical approaches, but animal experiments show that this is feasible, and clinical trials may soon be launched. Moreover, as the skin is the most accessible tissue in mammalian organisms, the opportunity to introduce genes through the skin opens up new avenues for modifying cell metabolism, aiming at coping with several different human health disorders. However, although protein therapy in XP patients has been a pioneer work in skin treatments, there is still a long way to go before submitting these patients to gene therapy protocols. While non-viral methods still provide low efficiency for gene correction, the successful approaches in preclinical and animals experiments all employ viral vectors, although these have several limitations and safety concerns. These are challenges to be overcome and efforts are in this direction. Recent developments with these vectors will probably provide benefits for XP patients. For example, lenti and adenoviral vectors may be employed in the development of reliable systems to facilitate patient diagnosis. Complementation studies with these vectors (in vitro and in vivo) may also address some old questions that will help to understand the origin of skin cancer, and also the developmental and neuronal problems of XP patients. The rapid advances and plentiful information gathered over the last few years are encouraging, and clearly indicate that we are on the right track towards gene therapy, targeting for improvement of the quality of life of XP patients.
